Colchicine Derivatives Allows Prolonged Survival of Cardiac Allograft in the Rat / 대한흉부외과학회지

ABSTRACT

BACKGROUND: Colchicine with its immunosupressive properties has been used with beneficial effects in autoimmune disease, such as Gout, etc. Whether colchicine, by virtue of the above property, could attenuate the process of cardiac allograft rejection in the rats is investigated in this report. MATERIAL AND METHOD: We compared the untreated group (Control, n=6), Cyclosporin A group (10 mg/kg, daily, n=20), and Colchicine derivative group (Colchicine 40 microgram/kg, n=20) of cardiac allografts in the rats. RESULT: In the untreated control group (n=6), all of 6 rats showed rejection within 3 weeks after cardiac allograft. In the cyclosporin A group (n=20), cyclosporin A (10 mg daily oral dose) was administered at a 10 mg daily oral dose and promoted long-term survival (over 100 days). The cyclosporin A group had one mortality at the 18th post-operative day due to infection. Furthermore, in the Colchicine derivatives group (n=20) with a daily IP (Intra Peritoneum) dose (40 ug/kg/day), we observed long-term survival.(>100 days), except for one rat that died of an anesthetic problem (respiratory failure) at the 9th post-operative day. CONCLUSION: Experiments have also been performed to evaluate whether the effect of colchicine derivatives allowed prolonged survival of cardiac allografts compared with the cyclosporin A administration group in the rats.